Innate Pharma (IPH)

Paris


Symbol		Exchange		Currency
IPH	·	Paris	·	EUR	Real-time
IPHA	·	NASDAQ	·	USD	Real-time
IPHYF	·	OTC Markets	·	USD	Delayed
IPH	·	TradeGate	·	EUR	Delayed

Currency in EUR

IPH Pro Research

1.8580

-0.3320(-15.16%)

Closed·14/08

Fair Value

Unlock Value

Day's Range

1.7540

1.9180

52 wk Range

1.0300

2.3300

IPH Income Statement

Assess the Innate Pharma income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the IPH net worth.

Period Ending:

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

2025

31/12

Total Revenues

aa.aa

24.7

57.67

61.64

20.12

9.01

Total Revenues Growth

aa.aa

-64.6%

+133.47%

+6.88%

-67.36%

-55.25%

Cost Of Revenues

aa.aa

51.66

56.02

51.98

43.62

Gross Profit

aa.aa

-22.3

6.01

5.62

-31.86

-34.62

Gross Profit Growth

aa.aa

-211.14%

+126.95%

-6.52%

-666.99%

-8.65%

Gross Profit Margin %

aa.aa

-90.28%

10.42%

9.12%

-158.34%

-384.4%

Other Operating Expenses, Total

aa.aa

25.52

22.44

18.29

19.72

19.39

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+34.44%	-12.1%	-18.49%	+7.81%	-1.63%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	25.52	22.44	18.29	19.72	19.39
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-47.83

-16.43

-12.67

-51.58

-54.01

Operating Income Growth

aa.aa

-4,532.34%

+65.66%

+22.87%

-307.1%

-4.72%

EBIT Margin %

aa.aa

-193.6%

-28.48%

-20.55%

-256.32%

-599.77%

Net Interest Expenses

aa.aa

0.02

0.26

2.54

1.87

0.88

Net Interest Expenses Growth

aa.aa

-93.27%

+1,620%

+883.33%

-26.25%

-53.07%

Interest Expense, Total

aa.aa

-0.31

-0.29

-0.64

-0.57

-0.44

Interest And Investment Income

aa.aa

0.33

0.55

3.18

2.44

1.32

Other Non Operating Expenses, Total

aa.aa

2.33

-0.81

2.56

0.23

3.95

EBT, Excl. Unusual Items

aa.aa

-45.48

-16.97

-7.57

-49.47

-49.18

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

-41

EBT, Incl. Unusual Items

aa.aa

-45.48

-57.97

-7.57

-49.47

-49.18

EBT, Incl. Unusual Items Growth

aa.aa

-5,385.89%

-27.47%

+86.94%

-553.51%

+0.59%

EBT, Incl. Unusual Items Margin

aa.aa

-184.1%

-100.52%

-12.28%

-245.87%

-546.11%

Income Tax Expense

aa.aa

Net Income to Company

aa.aa

-52.81

-58.1

-7.57

-49.47

-49.18

Minority Interest

aa.aa

Net Income

aa.aa

-52.81

-58.1

-7.57

-49.47

-49.18

Net Income Growth

aa.aa

+17.47%

-10.02%

+86.97%

-553.51%

+0.59%

Net Income Margin %

aa.aa

-213.78%

-100.74%

-12.28%

-245.87%

-546.11%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-45.48

-57.97

-7.57

-49.47

-49.18

Basic EPS - Continuing Operations

aa.aa

-0.57

-0.73

-0.09

-0.61

-0.55

Basic EPS - Continuing Operations Growth

aa.aa

-5,344.13%

-27.32%

+87.07%

-548.69%

+10.07%

Diluted EPS - Continuing Operations

aa.aa

-0.57

-0.73

-0.09

-0.61

-0.55

Diluted EPS - Continuing Operations Growth

aa.aa

-5,344.13%

-27.68%

+87.11%

-548.69%

+9.89%

Basic Weighted Average Shares Outstanding

aa.aa

79.54

79.64

80.45

81.05

89.59

Diluted Weighted Average Shares Outstanding

aa.aa

79.54

79.64

80.45

81.05

89.59

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-43.23

-12.02

-8.53

-50.27

-53.31

EBITDA Growth

aa.aa

-424.91%

+72.19%

+29.04%

-489.45%

-6.04%

EBITDA Margin %

aa.aa

-174.99%

-20.84%

-13.84%

-249.86%

-591.99%

EBIT

aa.aa

-47.83

-16.43

-12.67

-51.58

-54.01

* In Millions of EUR (except for per share items)

FAQ

What was Innate Pharma’s revenue at year end?

At the end of the last reported fiscal year, Innate Pharma (IPH) recorded total revenue of 9.0050 million EUR.

How much revenue did Innate Pharma report in the most recent quarter?

In its most recent quarterly earnings report, Innate Pharma posted revenue of 4.1450 million EUR.

What was Innate Pharma’s net income for the year?

For the full year, Innate Pharma reported net income of -49.1770 million EUR.

How much net income did Innate Pharma post in the last quarter?

In the most recent quarter, Innate Pharma (IPH) posted net income of -27.8330 million EUR.

What was Innate Pharma’s gross profit for the year?

Gross profit for the year was reported at -34.6150 million EUR.

How much gross profit did Innate Pharma generate last quarter?

Innate Pharma recorded gross profit of -18.9550 million EUR in its latest quarterly report.

What was Innate Pharma’s annual operating income?

For the full year, Innate Pharma (IPH) reported operating income of -54.0090 million EUR.

What was Innate Pharma’s operating income last quarter?

Quarterly operating income was -28.5820 million EUR.

What was Innate Pharma’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -28.2480 million EUR.

What was the quarter-over-quarter change in EBITDA for Innate Pharma?

EBITDA changed by -12.7170% million EUR compared to the last quarter.

How did Innate Pharma’s revenue change compared to the previous quarter?

Revenue changed by -14.7119% million EUR compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Innate Pharma?

In the latest quarter, gross profit changed by -21.0409% million EUR from the previous quarter.

S&P/TSX

36,730.27

-29.02

-0.08%

S&P/TSX 60

2,164.23

-4.11

-0.19%

US 30

53,674.10

-58.4

-0.11%

US 500

7,791.90

+6.2

+0.08%

S&P 500 VIX

14.25

-0.38

-2.60%

DAX

26,440.31

+140.57

+0.53%

Dollar Index

99.395

-0.164

-0.16%

Market Movers

Name	Last	Chg. %	Vol.
Enbridge	70.61	-1.20%	12.94M
Canadian Natural	66.41	+0.09%	9.20M
RBC	300.70	+0.42%	1.78M
Toronto Dominion Bank	172.61	+0.60%	2.58M
Shopify Inc	214.35	-3.00%	1.45M
Manulife Financial	61.73	+0.82%	4.15M
Suncor Energy	91.44	+0.23%	2.56M

Name	Last	Chg. %	Vol.
Prospectiva	0.90	+408.68%	18.00K
Metaguestai	0.03	+200.00%	93.75K
Metaguestai	0.03	+200.00%	93.75K
Lithos Energy	0.150	+200.00%	37.00K
DGTL	0.0250	+150.00%	10.00K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
Canadian Chrome	0.010	+100.00%	1.06M

Name	Last	Chg. %	Vol.
Lanebury Growth Capital	0.05	-68.75%	18.17K
Asep Medical Holdings	0.06	-60.71%	2.95K
Lithos Energy	0.10	-60.00%	8.00K
Carson River Ventures	0.04	-50.00%	1.25K
James Bay Resources Ltd	0.010	-50.00%	1.00K
Albert Labs International	0.005	-50.00%	1.00K
Molecule Holdings	0.005	-50.00%	20.11K

Trending Stocks

Name	Last	Chg. %	Vol.
Keel Infra	4.87	+4.96%	4.50M
HIVE Digital Tech	3.7200	+3.05%	2.34M
Celestica Inc.	465.23	-4.02%	329.60K
Canadian Natural	66.41	+0.09%	9.20M
TELUS	13.54	+0.59%	6.62M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaa	131.33	+52.90%	200.80
Aaaaa Aaa Aaaaaaa	101.88	+45.96%	148.70
Aaaaa Aaaaaaa A	9.02	+45.24%	13.10
Aaaaa Aaa	16.94	+44.81%	24.53
Aaaaaa	30.56	+43.89%	43.97
A Aaaaaaaaaaa	5.40	+43.06%	7.73
Aaaa Aaaaaa Aaa	34.06	+40.38%	47.81

Name	Last	Upside	Fair Value
Aaaaa	131.33	+52.90%	200.80
Aaaaa Aaa Aaaaaaa	101.88	+45.96%	148.70
Aaaaa Aaaaaaa A	9.02	+45.24%	13.10
Aaaaa Aaa	16.94	+44.81%	24.53
Aaaaaa	30.56	+43.89%	43.97
A Aaaaaaaaaaa	5.40	+43.06%	7.73
Aaaa Aaaaaa Aaa	34.06	+40.38%	47.81

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Innate Pharma (IPH)

IPH Income Statement

FAQ

What was Innate Pharma’s revenue at year end?

How much revenue did Innate Pharma report in the most recent quarter?

What was Innate Pharma’s net income for the year?

How much net income did Innate Pharma post in the last quarter?

What was Innate Pharma’s gross profit for the year?

How much gross profit did Innate Pharma generate last quarter?

What was Innate Pharma’s annual operating income?

What was Innate Pharma’s operating income last quarter?

What was Innate Pharma’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Innate Pharma?

How did Innate Pharma’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Innate Pharma?

Trending Stocks